The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.50
Bid: 18.00
Ask: 19.00
Change: 0.00 (0.00%)
Spread: 1.00 (5.556%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 18.50
RENX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

20 Dec 2018 17:20

RNS Number : 1932L
Renalytix AI PLC
20 December 2018
 

Renalytix AI plc

("RenalytixAI" or the "Company") 

 

Director/ PDMR Shareholding

 

The Company was informed that today, Christopher Mills, a non-executive director, completed the purchase of 3,168 ordinary shares of 0.25 pence each ("Ordinary Shares") in the Company at a price of 112 pence per share.

 

Following this purchase, Mr Mills is interested in 9,199,568 Ordinary Shares representing 17.09% of the total voting rights in the Company.

 

Enquiries:

 

Renalytix AI plc

www.renalytixai.com

James McCullough, CEO

Via Walbrook PR or Tel: +1 646 397 3970

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / James White / George Tzimas (Corporate Finance)

 

Tom Salvesen / Mia Gardner (Corporate Broking)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

     

 

 

  

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

 

Harwood Capital LLP (Harwood) as investment manager to North Atlantic Smaller Companies Investment Trust plc and Oryx

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Christopher Mills, non-exec director of the issuer and director of NASCIT and Oryx International Growth Fund Ltd

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Renalytix AI plc

b)

 

LEI

 

 

213800NTOH3FK3WER551

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 0.25 pence each

 

 

 

Identification code

GB00BYWL4Y04

 

 

 

b)

 

Nature of the transaction

 

 

Share purchase

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

112.00 pence

3,168

 

 

 

 

 

 

d)

 

Aggregated information

 

 

 

- Aggregated volume

3,168

 

 

- Price

£3,548.16

 

 

e)

 

Date of the transaction

 

20 December 2018

f)

 

Place of the transaction

 

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFKKDDOBDDFBB
Date   Source Headline
25th Feb 20207:00 amRNSConference attendance
8th Jan 20207:00 amRNSNew commercial testing facility opens in Utah
3rd Jan 20207:00 amRNSCMS Pricing Determination becomes effective
3rd Dec 20197:00 amRNSMedicare sets US national price for KidneyIntelX
21st Nov 20197:00 amRNSGrant of Options
19th Nov 20197:00 amRNSRenalytixAI attending City Event for Kidney Health
17th Oct 20197:00 amRNSPartnership with CDPHP on KidneyIntelX
14th Oct 20197:00 amRNSBoard appointment
1st Oct 20197:00 amRNSUS CPT® reimbursement code effective
30th Sep 20194:37 pmRNSResult of AGM
30th Sep 20198:00 amRNSUpdate on non-executive director appointment
30th Sep 20197:00 amRNSPreliminary Medicare Pricing Determination
6th Sep 20194:00 pmRNSPosting of Annual Report & Accounts &Notice of AGM
3rd Sep 20197:00 amRNSFinal Results
20th Aug 20197:00 amRNSNotice of Results
6th Aug 20197:00 amRNSExpansion of Chronic Kidney Disease Advisory Board
31st Jul 20194:30 pmRNSTotal Voting Rights
29th Jul 20197:00 amRNSThomas McLain Appointed as President and CCO
23rd Jul 20196:23 pmRNSResult of Placing & Total Voting Rights
23rd Jul 20197:01 amRNSProposed Placing to raise £12.0m (c.US$15.0m)
12th Jul 20197:00 amRNSUS Exec Order on Advancing American Kidney Health
9th Jul 20197:00 amRNSPositive Interim Results for Validation Study
8th Jul 20197:00 amRNSFractalDx Positive Results Published in JASN
1st Jul 20197:00 amRNSUS CPT® Code Granted for KidneyIntelX(TM)
7th Jun 20197:00 amRNSPositive results from FractalDx study published
4th Jun 20197:00 amRNSKidneyIntelX commercial scale production milestone
28th May 20197:00 amRNSCLIA Certificate Number issued for Renalytix Lab
21st May 20197:00 amRNSExpansion of FractalDx core investigator group
7th May 20197:00 amRNSUniversity Medical Center Groningen collaboration
2nd May 20192:05 pmRNSSecond Price Monitoring Extn
2nd May 20192:00 pmRNSPrice Monitoring Extension
2nd May 20197:00 amRNSFDA grants Breakthrough Device designation
26th Apr 20196:20 pmRNSAcquisition of further interest in Renalytix AI
26th Apr 20195:42 pmRNSDirector/PDMR Shareholding
2nd Apr 201912:55 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSPublication of confirmation study results
25th Mar 20197:00 amRNSHalf-year Report
22nd Mar 20197:00 amRNSRenalytixAI Forms Core Investigator Group
12th Mar 20197:00 amRNSInvestor briefing
14th Feb 20197:00 amRNSAppointment of Nomad and Joint Broker
13th Feb 20197:00 amRNSJoint venture partnership agreement with AKESOgen
6th Feb 20197:00 amRNSRenalytixAI Expands Leadership Team
23rd Jan 20197:00 amRNSInitiates Clinical Validation Study
21st Jan 20197:00 amRNSClarification re. lock-up restrictions
2nd Jan 20197:00 amRNSExercise of Option for Exclusive License
20th Dec 20185:20 pmRNSDirector/PDMR Shareholding
20th Dec 20187:01 amRNSPlanned appointment of joint broker & of NOMAD
19th Dec 20186:28 pmRNSDirector Dealing
17th Dec 20181:30 pmRNSHolding(s) in Company
9th Nov 201810:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.